secwatch.observer — SEC 8-K summary
======================================

Issuer:     MapLight Therapeutics, Inc. (MPLT)
CIK:        0001770069
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001193125-26-125062
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MapLight Q4 net loss $79.5M; cash $453M; Phase 2 readouts expected Q3 2026
--------------------------------------------------------------------------

- Net loss of $79.5M in Q4 2025 vs $21.2M year ago; FY2025 loss $161.2M vs $77.6M.
- Cash, equivalents and investments $453.1M as of Dec 31, 2025, expected to fund operations through 2027.
- Phase 2 ZEPHYR trial for schizophrenia: target enrollment (n=300) expected April 2026; topline results Q3 2026.
- Phase 2 IRIS trial for autism spectrum disorder completed enrollment; topline results expected Q3 2026.
- FDA Fast Track granted for ML-007C-MA in Alzheimer's disease psychosis; VISTA trial topline H2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770069/000119312526125062/0001193125-26-125062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770069/000119312526125062/mplt-20260326.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-125062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer